Urethrocutaneous fistula following VMMC: a case series from March 2013 to October 2019 in ZAZIC's voluntary medical male circumcision program in Zimbabwe.
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
16 Feb 2022
16 Feb 2022
Historique:
received:
31
08
2021
accepted:
02
02
2022
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Urethrocutaneous fistula (subsequently, fistula) is a rare adverse event (AE) in voluntary medical male circumcision (VMMC) programs. Global fistula rates of 0.19 and 0.28 per 100,000 VMMCs were reported. Management of fistula can be complex and requires expert skills. We describe seven cases of fistula in our large-scale VMMC program in Zimbabwe. We present fistula rates; provide an overview of initial management, surgical interventions, and patient outcomes; discuss causes; and suggest future prevention efforts. Case details are presented on fistulas identified between March 2013 and October 2019. Among the seven fistula clients, ages ranged from 10 to 22 years; 6 cases were among boys under 15 years of age. All clients received surgical VMMC by trained providers in an outreach setting. Clients presented with fistulae 2-42 days after VMMC. Secondary infection was identified in 6 of 7 cases. Six cases were managed through surgical repair. The number of repair attempts ranged from 1 to 10. One case healed spontaneously with conservative management. Fistula rates are presented as cases/100,000 VMMCs. Fistula is an uncommon but severe AE that requires clinical expertise for successful management and repair. High-quality AE surveillance should identify fistula promptly and include consultation with experienced urologists. Strengthening provider surgical skills and establishment of standard protocols for fistula management would aid future prevention efforts in VMMC programs.
Sections du résumé
BACKGROUND
BACKGROUND
Urethrocutaneous fistula (subsequently, fistula) is a rare adverse event (AE) in voluntary medical male circumcision (VMMC) programs. Global fistula rates of 0.19 and 0.28 per 100,000 VMMCs were reported. Management of fistula can be complex and requires expert skills. We describe seven cases of fistula in our large-scale VMMC program in Zimbabwe. We present fistula rates; provide an overview of initial management, surgical interventions, and patient outcomes; discuss causes; and suggest future prevention efforts.
RESULTS
RESULTS
Case details are presented on fistulas identified between March 2013 and October 2019. Among the seven fistula clients, ages ranged from 10 to 22 years; 6 cases were among boys under 15 years of age. All clients received surgical VMMC by trained providers in an outreach setting. Clients presented with fistulae 2-42 days after VMMC. Secondary infection was identified in 6 of 7 cases. Six cases were managed through surgical repair. The number of repair attempts ranged from 1 to 10. One case healed spontaneously with conservative management. Fistula rates are presented as cases/100,000 VMMCs.
CONCLUSION
CONCLUSIONS
Fistula is an uncommon but severe AE that requires clinical expertise for successful management and repair. High-quality AE surveillance should identify fistula promptly and include consultation with experienced urologists. Strengthening provider surgical skills and establishment of standard protocols for fistula management would aid future prevention efforts in VMMC programs.
Identifiants
pubmed: 35172795
doi: 10.1186/s12894-022-00973-1
pii: 10.1186/s12894-022-00973-1
pmc: PMC8849017
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Informations de copyright
© 2022. The Author(s).
Références
Urol Int. 2007;78(3):235-40
pubmed: 17406133
PLoS One. 2019 Jun 10;14(6):e0218137
pubmed: 31181096
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S88-95
pubmed: 22797745
Biomed Res Int. 2014;2014:375285
pubmed: 25250318
PLoS One. 2018 Sep 7;13(9):e0203292
pubmed: 30192816
J Urol. 2002 Aug;168(2):726-30; discussion 729-30
pubmed: 12131360
BMC Public Health. 2014 Aug 18;14:858
pubmed: 25134856
BMC Health Serv Res. 2019 Nov 21;19(1):855
pubmed: 31752838
MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):337-339
pubmed: 29565839
Glob Health Sci Pract. 2014 Jan 09;2(1):93-102
pubmed: 25276565
BMC Urol. 2021 Feb 12;21(1):23
pubmed: 33579261
BMC Urol. 2019 Jul 11;19(1):65
pubmed: 31296191
J Int AIDS Soc. 2014 Nov 17;17:19275
pubmed: 25406951
J Int AIDS Soc. 2019 Jul;22(7):e25369
pubmed: 31368235
Bull World Health Organ. 2012 Oct 1;90(10):773-81
pubmed: 23109745
BMC Health Serv Res. 2016 Feb 17;16:61
pubmed: 26888178
BJU Int. 2009 Aug;104(4):529-32
pubmed: 19389002
BMC Urol. 2020 Apr 25;20(1):45
pubmed: 32334596
J Int AIDS Soc. 2017 Feb 20;19(1):21394
pubmed: 28362066
Ann Plast Surg. 2000 Apr;44(4):381-6
pubmed: 10783093
BJU Int. 2000 Aug;86(3):318-26
pubmed: 10930940
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S229-S235
pubmed: 29617777
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e13-23
pubmed: 25942466